APS

29th APS Annual Convention · 2017

Effects of Galantamine on Laboratory Choice Task in Daily Smokers

Boston, MA · May 2017

Poster Session · Clinical Science

  • Robert MacLean
    Yale University
  • Robert MacLean
    VA Connecticut Healthcare System - West Haven
  • Mehmet Sofuoglu
    Yale University
  • Mehmet Sofuoglu
    VA Connecticut Healthcare System - West Haven
  • Andrew Waters
    Uniformed Service University of the Health Sciences

Abstract

Galantamine (an Acetylcholinesterase inhibitor) is a promising new treatment for tobacco addiction that is believed to attenuate the acute effects of nicotine. Results of a cigarette choice task in daily smokers reveal Galantamine treatment group, compared to placebo, chose monetary reward over opportunity to smoke more frequently.

Substance Abuse

← Poster Session XI